Edwards Lifesciences Corporatio

Edwards Lifesciences provides products and technologies for structural heart disease and critical care monitoring globally. Products include transcatheter heart valves and surgical valve solutions. Critical care solutions include hemodynamic monitoring systems and a monitoring platform. The company also offers software to predict hypotension and alert clinicians. Products are distributed through a direct sales force and independent distributors. Founded in 1958, Edwards Lifesciences is headquartered in Irvine, California.

Overview

Sector

Medical Devices

Target Price

6.9 USD

Current Price

81.2 USD

Potential

-91%

Strengths

Current Price to Earnings Ratio (11.35) is lower than the sector mean (123.56).
The company has low debt. Net Debt to EBITDA Ratio is -1.33 and it is lower than the sector mean.
Strong EBITDA Margin of 32.41%.

Weaknesses

With a depreciation Potential of -91.41%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The Price to Free Cash Flow ratio (182.24) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	11.4
EV/EBITDA	25.8
Price/Free Cash Flow'	183.8
ROIC	5.1%
Net Debt/EBITDA	-1.3